Studies have found that the gene FEZF1-AS1 can act as an “oncogene” for gastric cancer partly through suppressing P21 expression and may serve as a candidate prognostic biomarker for new therapies of gastric cancer patients. Here, FEZF1 is linked to gastric cancer.